Selective regulation of human immunodeficiency virus-infected CD4+ lymphocytes by a synthetic immunomodulator leads to potent virus suppression in vitro and in hu-PBL-SCID mice

Journal of Virology

Volumn 75, Issue 15, 2001, Pages 6941-6952

  Bahr, G M ^a   Darcissac, E C A ^a   Casteran N ^a   Amiel, C ^a   Cocude, C ^a   Truong, M J ^a   Dewulf, J ^a   Capron, A ^a   Mouton, Y ^a  

^a INSTITUT PASTEUR DE LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MURABUTIDE; PHYTOHEMAGGLUTININ; VIRUS DNA;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DNA SYNTHESIS; FEMALE; GENE EXPRESSION; HOST RESISTANCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; T LYMPHOCYTE; VIRUS LOAD; VIRUS REPLICATION;

ACETYLMURAMYL-ALANYL-ISOGLUTAMINE; ADJUVANTS, IMMUNOLOGIC; ADULT; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL DIVISION; CELL SURVIVAL; CELLS, CULTURED; CYTOKINES; DNA, VIRAL; DOWN-REGULATION; GENE EXPRESSION REGULATION, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MICE; MICE, SCID; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTORS, CCR5; RECEPTORS, CXCR4; RECEPTORS, INTERLEUKIN-2; RNA, MESSENGER; RNA, VIRAL; VIRAL LOAD; VIRUS REPLICATION;

EID: 0034947908     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.75.15.6941-6952.2001     Document Type: Article

References (77)

1. Bacterial lipopolysaccharide is a potent inhibitor of HIV-1 replication in T lymphocytes and macrophages
2. Interleukin-16 (IL-16) inhibits human immunodeficiency virus replication in cells from infected subjects, and serum IL-16 levels drop with disease progression
3. Control of IgE responses. 4. Isotype-specific suppression of peak BPO-specific IgE antibody-forming cell responses and of BPO-specific IgE in serum by muramyldipeptide or murabutide after administration to mice by garage
4. Immunological activities of muramyl peptides
5. Immunopharmacological activities and clinical development of muramyl peptides with particular emphasis on murabutide
6. Synergistic effects between recombinant interleukin-2 and the synthetic immunomodulator murabutide: Selective enhancement of cytokine release and potentiation of antitumor activity
7. Enhancement in vivo of the antiinflammatory and antitumor activities of type I interferon by association with the synthetic immunomodulator murabutide
8. Activation of integrated provirus requires histone acetyltransferase, p300 and P/CAF are coactivators for HIV-1 Tat
9. The use of cyclosporine, FK506, and SDZ NIM811 to prevent CD25-quiescent peripheral blood mononuclear cells from producing human immunodeficiency virus
10. Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection
11. Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage
12. Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo
13. Biological activity of a new synthetic muramyl peptide adjuvant devoid of pyrogenicity
14. Prophylactic and therapeutic effects of murabutide in OF1 mice infected with influenza A/H3N2 (A/Texas/1/77) virus
15. Relationship between preexisting viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy
16. Pentoxifylline improves cell-mediated immunity and reduces human immunodeficiency virus (HIV) plasma viremia in asymptomatic HIV-seropositive persons
17. The synthetic immunomodulator murabutide controls human immunodeficiency virus type 1 replication at multiple levels in macrophages and dendritic cells
18. Suppression of HIV-1 infection in linomide-treated SCID-hu-PBL mice
19. Pretreatment by tubulin agents decreases C-MYC induction in human colon carcinoma cell line HT29-D4
20. Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease
21. Human immunodeficiency virus type 1 strains R5 and X4 induce different pathogenic effects in hu-PBL-SCID mice, depending on the state of activation/differentiation of human target cells at the time of primary infection
22. Colony-stimulating activity induced by synthetic muramyl peptides: Variation with chemical structure and association with anti-infectious activity
23. Therapeutic efficacy of liposome-encapsulated ribavirin and muramyl tripeptide in experimental infection with influenza or herpes simplex virus
24. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy
25. Specific binding of glucosaminylmuramyl peptides to histones
26. Differences in HIV replication in CD4+ lymphocytes are not related to beta-chemokine production
27. Generation of alloantigen-stimulated anti-human immunodeficiency virus activity is associated with HLA-A*02 expression
28. A human nuclear shuttling protein that interacts with human immunodeficiency virus type 1 matrix is packaged into virions
29. CNI-H0294, a nuclear importation inhibitor of the human immunodeficiency virus type 1 genome, abrogates virus replication in infected activated peripheral blood mononuclear cells
30. Immunotherapy of murine visceral leishmaniasis with murine recombinant interferon-gamma and MTP-PE encapsulated in liposomes
31. TNF-alpha-induced secretion of C-C chemokines modulates C-C chemokine receptor 5 expression on peripheral blood lymphocytes
32. Biological properties of bacterial peptidoglycan
33. Immunomodulatory treatment of Mycobacterium avium complex bacteremia in patients with AIDS by use of recombinant granulocyte-macrophage colony-stimulating factor
34. Suppression of in vivo IgE and tissue IL-4 mRNA induction by SDZ 280.636, a synthetic muramyl dipeptide derivative
35. Muramyl peptides. Variation of somnogenic activity with structure
36. Retroviral cDNA integration: Stimulation by HMG I family proteins
37. Dendritic cell infection, depletion and dysfunction in HIV-infected individuals
38. Gene expressions of lipopolysaccharide receptors, toll-like receptors 2 and 4, are differently regulated in mouse T lymphocytes
39. Regulation of HIV production by blood mononuclear cells from HIV-infected donors. I. Lack of correlation between HIV-1 production and T cell activation
40. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants
41. Splicing variability in HIV type 1 revealed by quantitative RNA polymerase chain reaction
42. Effect of granulocyte colony-stimulating factor (G-CSF) in human immunodeficiency virus-infected patients: Increase in numbers of naive CD4 cells and CD34 cells makes G-CSF a candidate for use in gene therapy or to support antiretroviral therapy
43. Enhancement of the effectiveness of antimicrobial therapy by muramyl peptide immunomodulators
44. How immune-based interventions can change HIV therapy
45. Cell-associated HIV-1 messenger RNA and DNA in T-helper cell and monocytes in asymptomatic HIV-1-infected subjects on HAART plus an inactivated HIV-1 immunogen
46. Quantitative competitive polymerase chain reaction for accurate quantitation of HIV DNA and RNA species
47. Inhibition of human immunodeficiency virus type 1 replication prior to reverse transcription by influenza virus stimulation
48. Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation
49. Enhancement by muramyl peptides of the protective response of interferon-alpha/beta against encephalomyocarditis virus infection
50. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy
51. Influence of a muramyl dipeptide on human blood leukocyte functions and their membrane antigens
52. Comparison of the immuno- and neuropharmacological activities of MDP and Murabutide
53. T-cell dysfunctions in hu-PBL-SCID mice infected with human immunodeficiency virus (HIV) shortly after reconstitution: In vivo effects of HIV on highly activated human immune cells
54. Immune control of HIV-1 after early treatment of acute infection
55. Human primary immune response in SCID mice engrafted with human peripheral blood lymphocytes
56. Therapeutic immunisation with recombinant gp160 in HIV-1 infection: A randomised double-blind placebo-controlled trial
57. Cloning and functional analysis of multiply spliced mRNA species of human immunodeficiency virus type 1
58. HIV-induced immunopathogenesis
59. IL-7 up-regulates HIV-1 replication in naturally infected peripheral blood mononuclear cells
60. Immune reconstitution in HIV-infected individuals - What will it take?
61. Purified histone acetyltransferase complexes stimulate HIV-1 transcription from preassembled nucleosomal arrays
62. Antiviral activity, of 2′-deoxy-3′-oxa-4′-thiocytidine (BCH-10652) against lamivudine-resistant human immunodeficiency virus type 1 in SCID-hu Thy/Liv mice
63. Enhancement of carrier-specific helper T cell function by the synthetic adjuvant, N-acetyl muramyl-L-alanyl-D-isoglutamine (MDP)
64. Muramyl peptide-binding sites are located inside target cells
65. Expression of the c-myc proto-oncogene is essential for HIV-1 infection in activated T cells
66. Infection of CD4+ memory T cells by HIV-1 requires expression of phosphodiesterase 4
67. Comprehensive gene expression profile of LPS-stimulated human monocytes by SAGE
68. Clinical evaluation of the immunoadjuvant murabutide, a derivative of MDP, administered with a tetanus toxoid vaccine
69. Involvement of T cells in enhanced resistance to Klebsiella pneumoniae septicemia in mice treated with liposome-encapsulated muramyL tripeptide phosphatidylethanolamine or gamma interferon
70. 125I-labelled aryl-azide derivatives of muramyldipeptide
71. Chemokines are the main proinflammatory mediators in human monocytes activated by Staphylococcus aureus, peptidoglycan, and endotoxin
72. Specific binding of soluble peptidoglycan and muramyldipeptide to CD14 on human monocytes
73. Immunostimulating agents: What next? A review of their present and potential medical applications
74. Muramyl peptides and polyinosinic-polycytidylic acid given to mice prior to influenza virus challenge reduces pulmonary disease and mortality
75. Altered cytokine production and accessory cell function after HIV-1 infection
76. Differences in proinflammatory activity of several immunomodulatory derivatives of muramyl dipeptide (MDP) with special reference to the mechanism of the MDP effects
77. Oral administration of muramyl dipeptide into mice modulates cell proliferation, immunoglobulin synthesis and cytokine mRNA levels in gut associated lymphoid tissues